Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02220842 · ClinicalTrials.gov registry record · Phase 1

A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

A Phase 1 study of Lymphoma, sponsored by Hoffmann-La Roche.

Completed
Registry status
Phase 1
Development phase
96
Enrollment target
15
Study locations

NCT02220842 is a Phase 1 study of Lymphoma that has completed, run by Hoffmann-La Roche. The registered enrollment target is 96 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (80% lower). The trial reports 15 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02220842, a Phase 1 study of Lymphoma, has completed, sponsored by Hoffmann-La Roche.

COMPLETED
Registry status
Phase 1
Development phase
96 participants
Enrollment target
15
Study locations

Study Summary

This open-label, multicenter, global study is designed to assess the safety, tolerability, preliminary efficacy, and pharmacokinetics of intravenous atezolizumab (MPDL3280A) and obinutuzumab in participants with refractory or relapsed follicular lymphoma (FL) or atezolizumab and obinutuzumab or tazemetostat administered in participants with refractory or relapsed diffuse large B-cell lymphoma (DLBCL). The anticipated duration of this study is approximately 4.5 years.

Conditions Studied

Lymphoma

Interventions

  • DRUG Obinutuzumab
  • DRUG Atezolizumab
  • DRUG Tazemetostat

Study Locations (15)

Other

  • Hopital Claude Huriez - CHU Lille; Service des maladies du sang - Lille
  • Hopital Saint Eloi - Montpellier
  • Hôpital Saint-Louis - Paris
  • Centre Hospitalier Lyon Sud - Pierre-Bénite
  • Institut Gustave Roussy - Villejuif
  • Universitaetsklinikum Freiburg - Freiburg im Breisgau
  • Barts Hospital - London

California

  • City of Hope National Medical Center - Duarte

Indiana

  • Fort Wayne Neurological Center - Fort Wayne

New Jersey

  • Hackensack University Medical Center - Hackensack

New York

  • Sloan Kettering Cancer Center - New York

North Carolina

  • University of North Carolina at Chapel Hill - Chapel Hill

Texas

  • MD Anderson Cancer Center - Houston

Washington

  • UW- Fred Hutchinson Cancer Center - Seattle

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2014-12-18
Est. Completion 2020-01-21
Phase Phase 1

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02220842

The ClinicalTrials.gov registry entry for NCT02220842 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (80% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Obinutuzumab is the first listed.

NCT02220842 reports 15 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Indiana.

Frequently Asked Questions

What is clinical trial NCT02220842 about?

NCT02220842 is a clinical study titled "A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma". This open-label, multicenter, global study is designed to assess the safety, tolerability, preliminary efficacy, and pharmacokinetics of intravenous atezolizumab (MPDL3280A) and obinutuzumab in participants with refractory or relapsed follicular lymphoma (FL) or atezolizumab and obinutuzumab or taze...

What is the current status of trial NCT02220842?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2014-12-18. Estimated completion is 2020-01-21.

What conditions does trial NCT02220842 study?

This clinical trial studies the following conditions: Lymphoma.

What interventions are being tested in trial NCT02220842?

The interventions under investigation include: Obinutuzumab (DRUG), Atezolizumab (DRUG), Tazemetostat (DRUG).

Who is sponsoring clinical trial NCT02220842?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02220842 being conducted?

This trial has 15 study locations across California, Indiana, New Jersey, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.